RECHERCHE :   Cancers hématologiques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
AMGEN 20150136: An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices
Leucémie lymphoblastique aigüe (Acute Lymphoblastic leukaemia)
registre
CHUV, HUG
HOVON 150: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy
III
HUG
HOVON 155 A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) adult AML and high-risk myelodysplasia (MDS) (IPSS-R > 4.5) patients
leucémie aiguë myéloïde (LAM) ou syndrome myélodysplasique (SMD) à haut risque de progression chez des patient-e-s âgé-e-s ou fragiles
II
CHUV
HOVON 156: A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy
AML or MDS-EB2
III
HUG
MALIBU:Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas
untreated marginal zone lymphomas
II
HUG